Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06798896 · ClinicalTrials.gov registry record · Phase 2
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures
A Phase 2 study of Focal Onset Seizures, sponsored by Supernus Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 258
- Enrollment target
- 1
- Study location
NCT06798896 is a Phase 2 study of Focal Onset Seizures that is actively recruiting participants, run by Supernus Pharmaceuticals. The registered enrollment target is 258 participants, above the 218-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (18% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06798896, a Phase 2 study of Focal Onset Seizures, is actively recruiting participants, sponsored by Supernus Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 258 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SPN-817
Study Locations (1)
Florida
- Medsol Clinical Research Center - Port Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2024-12-30 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06798896
The ClinicalTrials.gov registry entry for NCT06798896 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 218-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (18% higher). The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Focal Onset Seizures appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06798896 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06798896 about?
NCT06798896 is a clinical study titled "RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures". This is a Phase 2 double-blind, randomized, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy, safety, and tolerability of SPN-817 in adults with focal onset seizures.
What is the current status of trial NCT06798896?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 258 participants. The study started on 2024-12-30. Estimated completion is 2026-10.
What conditions does trial NCT06798896 study?
This clinical trial studies the following conditions: Focal Onset Seizures.
What interventions are being tested in trial NCT06798896?
The interventions under investigation include: Placebo (DRUG), SPN-817 (DRUG).
Who is sponsoring clinical trial NCT06798896?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06798896 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Focal Onset Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy
COMPLETED · Phase 2
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)
RECRUITING · Phase 3
-
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.